- Trials with a EudraCT protocol (22)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
22 result(s) found for: Laryngeal cancer.
Displaying page 1 of 2.
| EudraCT Number: 2016-002082-65 | Sponsor Protocol Number: 2016-002082-65 | Start Date*: 2016-10-26 | |||||||||||||||||||||
| Sponsor Name:Andreas Kjaer | |||||||||||||||||||||||
| Full Title: Phase II trial: uPAR-PET/CT for prognostication in head- and neck cancer | |||||||||||||||||||||||
| Medical condition: Head and neck cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2007-004603-35 | Sponsor Protocol Number: REACH | Start Date*: 2009-04-28 | |||||||||||||||||||||
| Sponsor Name:University of Heidelberg | |||||||||||||||||||||||
| Full Title: Radiotherapy (IMRT), Erbitux And Chemotherapy For Unresectable Carcinomas Of Head and Neck. REACH-Study | |||||||||||||||||||||||
| Medical condition: Histologically confirmed locally advanced (stage III or IV), non-metastatic squamous cell carcinoma of oro-, hypopharynx or larynx (T2-4, NX, M0). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2013-003622-86 | Sponsor Protocol Number: CA209-141 | Start Date*: 2014-06-05 | |||||||||||||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||
| Full Title: An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) | |||||||||||||||||||||||
| Medical condition: Squamous cell carcinoma of the head and neck | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: IT (Completed) GB (Completed) ES (Completed) DE (Completed) NL (Completed) FR (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2020-003474-45 | Sponsor Protocol Number: 74742 | Start Date*: 2023-02-17 |
| Sponsor Name:Erasmus University Medical Center | ||
| Full Title: The STELLAR trial: Fluorescence-guided surgery in laryngeal- and hypopharyngeal cancer: a feasibility trial | ||
| Medical condition: Squamous cell carcinoma of the larynx and hypoharynx | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-006091-38 | Sponsor Protocol Number: DeLOSII | Start Date*: 2007-05-31 | ||||||||||||||||
| Sponsor Name:Universität Leipzig | ||||||||||||||||||
| Full Title: Randomisierte Phase II Screeningstudie zum Einsatz einer TP/TPF-Chemotherapie (Kurzinduktion) vor TP/TPF-Induktion, Radiotherapie mit und ohne Cetuximab in der Primärtherapie des nur durch Laryngek... | ||||||||||||||||||
| Medical condition: by laryngectomy operable carcinoma of the larynx and the hypopharynx | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) AT (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2008-001354-41 | Sponsor Protocol Number: UCLONCO08-001 | Start Date*: 2008-04-11 | ||||||||||||||||||||||||||
| Sponsor Name:Cliniques Universitaires St Luc, Centre du Cancer | ||||||||||||||||||||||||||||
| Full Title: Neoadjuvant cetuximab monotherapy followed by surgery in squamous cell carcinoma of head and neck: phase I/II study | ||||||||||||||||||||||||||||
| Medical condition: patients with squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx newly diagnosed and eligible for surgery. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: BE (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2006-002187-25 | Sponsor Protocol Number: Accrobat | Start Date*: 2007-01-26 |
| Sponsor Name:Radiumhemmet, Karolinska University Hospital | ||
| Full Title: A multicenter, open label, non-randomised phase II study with induction chemotherapy with Cisplatin and 5-fluorouracil as combined with accelerated radiotherapy and Erbitux for locally advanced unr... | ||
| Medical condition: Patient with locally advanced non-resectable squamous cell carcinoma of the head and neck stage III or IV, oral, oropharyngeal, laryngeal or hypopharyngeal cancer, non-resectable. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-004875-38 | Sponsor Protocol Number: PRIMEH&N | Start Date*: 2020-11-12 | |||||||||||||||||||||
| Sponsor Name:Fondazione GONO | |||||||||||||||||||||||
| Full Title: The induction and maintenance treatment with PARP inhibitor and immunotherapy in HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) | |||||||||||||||||||||||
| Medical condition: HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2014-003833-24 | Sponsor Protocol Number: AGMT_HNO_PN | Start Date*: 2016-06-30 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:AGMT – Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Randomized phase III study: Supplemental parenteral nutrition for patients with locally advanced inoperable tumors of the head and neck, receiving definitive radiotherapy with Cetuximab or Cisplatin | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Locally advanced inoperable tumors of the head and neck under definitive radiotherapy with Cetuximab or Cisplatin | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: AT (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2004-002963-25 | Sponsor Protocol Number: EU-HNBE-2003 | Start Date*: 2005-03-10 |
| Sponsor Name:Genetronics, Inc. | ||
| Full Title: An Open-Label Study using the MedPulser Electroporation System To Treat Head and Neck Cancer | ||
| Medical condition: Histologically confirmed primary oral cavity, primary pharyngeal, primary laryngeal, salivary gland, limited recurrent and second primary tumors. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2012-001416-27 | Sponsor Protocol Number: MEC-2012-130 | Start Date*: 2012-11-15 |
| Sponsor Name:Erasmus MC | ||
| Full Title: Treatment of Cancer in the head and Neck: The Role of Hyperbaric Oxygen in Reducing Swallowing Problems | ||
| Medical condition: Nasopharynx, Oropharynx, Oral Cavity, Hypopharynx, Larynx | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-005188-34 | Sponsor Protocol Number: GORTEC2014-03 | Start Date*: 2015-04-20 | |||||||||||
| Sponsor Name:GORTEC | |||||||||||||
| Full Title: Phase III trial of laryngeal preservation comparating Induction chemotherapy with cisplatin, 5-fluorouracil and docetaxel (TPF) followed by radiotherapy and concomitant administration of radiother... | |||||||||||||
| Medical condition: | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-005540-99 | Sponsor Protocol Number: AGMT_HNO2 | Start Date*: 2013-03-05 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:AGMT – Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH | ||||||||||||||||||||||||||||||||||||||
| Full Title: Randomised Phase II Pilot Studiy: Induction Chemotherapy with Docetaxel, Cisplatin und Cetuximab versus Docetaxel, Cisplatin und 5 FU followed by Radiotherapy with Cetuximab for locally advanced o... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Locally advanced or not resectable Carcinoma of the Head and Neck | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: AT (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2005-001132-72 | Sponsor Protocol Number: IEO S233/105 | Start Date*: 2005-09-26 | |||||||||||
| Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
| Full Title: A Phase 2 Study of combined modality treatment with primary chemotherapy followed by endoscopic laser resection in intermediate stage laryngeal squamous cell carcinoma. | |||||||||||||
| Medical condition: SQUAMOUS CELL CARCINOMA OF THE LARYNGX | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-013438-26 | Sponsor Protocol Number: 135 | Start Date*: 2010-08-24 |
| Sponsor Name:Karolinska University Hospital | ||
| Full Title: A multicentre, open label, randomised phase II study with docetaxel (Taxotere®), cisplatin and 5-fluorouracil as induction chemotherapy, combined with hyperfractionated radiotherapy and cetuximab ... | ||
| Medical condition: Patients with non-resectable stage III-IV head and neck cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-005219-16 | Sponsor Protocol Number: GE-135-003 | Start Date*: 2010-12-06 |
| Sponsor Name:GE Healthcare Ltd | ||
| Full Title: A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis via the Expression of avb3 Integrin Receptors by [18F]AH111585 PET Imaging | ||
| Medical condition: Adult subjects with Primary or metastatic tumour lesion of one of the following types: high-grade glioma, including GBM, anaplastic astrocytoma, and anaplastic oligodendroglioma; lung cancer, inclu... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2018-002971-17 | Sponsor Protocol Number: FG-2018/05 | Start Date*: 2019-07-18 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Centre Georges-François Leclerc | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Precision medicine phase II study evaluating the efficacy of a double immunotherapy by Durvalumab and Tremelimumab combined with Olaparib in patients with solid cancers and carriers of homologous r... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Patients with the following solid malignancy: • Metastatic breast cancer • Metastatic prostate cancer • Metastatic lung cancer • Metastatic head and neck • Metastatic endometrial cancer • M... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2017-002857-12 | Sponsor Protocol Number: GO40241 | Start Date*: 2018-04-26 | |||||||||||
| Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||
| Full Title: A PHASE III, DOUBLE-BLINDED, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT TREATMENT WITH ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY I... | |||||||||||||
| Medical condition: Early Stage Resectable Non-small cell lung cancer (NSCLC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) SI (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) HU (Completed) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-002667-33 | Sponsor Protocol Number: 24051 | Start Date*: 2007-06-18 | |||||||||||
| Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||
| Full Title: Phase I/II study on induction chemotherapy followed by chemoradiation with or without lapatinib, a dual EGFR/ErbB2 kinase inhibitor, in patients with locally advanced resectable larynx and hypophar... | |||||||||||||
| Medical condition: locally advanced resectable larynx and hypopharynx squamous cell carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-004189-37 | Sponsor Protocol Number: HCQHNLcancer | Start Date*: 2022-03-09 | |||||||||||||||||||||||||||||||
| Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||||||||||||||||||||||
| Full Title: Role of Hydroxychloroquine in therapeutic strategy of Head and Neck cancer and Non-small cell lung cancer | |||||||||||||||||||||||||||||||||
| Medical condition: Patients affected by Resectable Head and Neck (HN) cancer (only Squamous Cell Carcinoma of the oral cavity or larynx), or Resectable Non-small cell lung cancer (NSCLC, only Lung Squamous Cell Carci... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.